Video: Who Am I?| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: hospital

Healthcare Investors Brace for Busy Week as U.S. Conference Kicks Off

Lewis Krauskopf  |  January 11, 2016

(Reuters)—Healthcare investors can expect a volatile week starting on Monday when the sector’s biggest financial event hits San Francisco. The annual JP Morgan healthcare conference, in which many healthcare companies present product and financial news to would-be investors, has been credited for helping the January out-performance of the healthcare sector in recent years. But after…

Filed under:Professional Topics Tagged with:Affordable Care Act (ACA)Health InsuranceObamacarepharmaceutical company

Biosimilars Seek Regulatory Approval in the U.S. & Europe; Plus MTX Underused in the U.S.

Michele B. Kaufman, PharmD, BCGP  |  January 6, 2016

In Europe, an etanercept biosimilar is getting closer to being approved to treat RA and more, and in the U.S., an application for an adalimumab biosimilar has been submitted for FDA approval. Also, an analysis of methotrexate use in the U.S. shows that therapy may actually be underused for RA…

Filed under:Biologics/DMARDsConditionsDrug UpdatesPsoriatic Arthritis Tagged with:axial spondyloarthritis (SpA)BiosimilarsEuropean Medicines AgencyMethotrexateplaque psoriasisPsoriatic ArthritisRheumatoid Arthritis (RA)

ACPA-Positive & ACPA-Negative Patients with RA: The Difference Begins in the Lungs

Lara C. Pullen, PhD  |  January 4, 2016

A new study from Stockholm, Sweden, strengthens the link between the lungs and anti-citrullinated protein antibody (ACPA)–positive RA. After analyzing the bronchial tissue of untreated patients with early RA, researchers found the patients’ lungs had signs of immune cell accumulation and activation…

Filed under:ConditionsRheumatoid Arthritis Tagged with:ACPAanti-citrullinated protein antibodieslunglung diseaseRheumatoid Arthritis (RA)

Researchers Describe Controversial Study of Surgeon Training

Andrew M. Seaman  |  January 3, 2016

(Reuters Health)—Whether surgical trainees should be able to work long shifts is a matter of fierce debate, and the methods of a controversial study aimed at answering that question were outlined in a top surgical journal. The results won’t be available until February. In the meantime, critics of the study say it exposed residents and…

Filed under:Career DevelopmentEducation & TrainingProfessional TopicsWorkforce Tagged with:medical studentssurgeryTraining

Original Sin—Researchers Look for Infectious Triggers of Rheumatic Disease & the Best Options to Block the Process

Susan Bernstein  |  December 29, 2015

SAN FRANCISCO—Two hundred years ago, physicians knew nothing about what caused various forms of arthritis. Today, we have more clues about what may trigger rheumatic diseases, but still can’t pinpoint the culprits that set scores of inflammatory conditions in motion. Researchers discussed some of the background and recent findings that point to what immunologists call…

Filed under:ConditionsRheumatoid Arthritis Tagged with:ACR/AHRP Annual MeetingAutoimmune diseaseEpstein-Barr virus (EBV)systemic lupus erythematosus (SLE)

New Blood Thinner ‘Antidote’ to Help Doctors Move Past Warfarin

Bill Berkrot  |  December 28, 2015

NEW YORK (Reuters)—A new class of blood thinners that competes with widely used warfarin should get a boost next year when an “antidote” that can reverse the medications’ effects in an emergency is expected to enter the market, according to top U.S. heart doctors and investors. Xarelto, from Bayer AG and Johnson & Johnson, and…

Filed under:Drug Updates Tagged with:anticoagulantblood clotwarfarin

People with Schizophrenia at Higher Risk of Osteoporosis

David Douglas  |  December 27, 2015

NEW YORK (Reuters Health)—Pooled data indicate that bone mineral density (BMD) is significantly lower in patients with schizophrenia than in healthy controls, according to Taiwanese researchers. Dr. Ping-Tao Tseng tells Reuters Health by email that the “evidence indicates the importance of further screening for the risk of osteoporosis in young-aged schizophrenic patients . . ….

Filed under:ConditionsOsteoarthritis and Bone Disorders Tagged with:bone mineral density (BMD)FracturesMental HealthOsteoporosisSchizophrenia

Biologic DMARDs Prove Effective for Psoriatic Arthritis & Combination DMARDs Show Promise for RA

Michele B. Kaufman, PharmD, BCGP  |  December 25, 2015

In clinical trials, ixekizumab and adalimumab proved safe and effective in treating adults with active psoriatic arthritis. Also, the combination therapy of certolizumab pegol plus methotrexate was more effective than placebo for treating severe RA…

Filed under:Biologics/DMARDsConditionsDrug UpdatesPsoriatic Arthritis Tagged with:adalimumabBiologicsCertolizumab Pegolcombination therapyixekizumabMethotrexatePsoriatic ArthritisRheumatoid Arthritis (RA)

Case Report: Sternoclavicular Erosions in a Patient with Uncontrolled RA

Diana M. Girnita, MD, PhD, Avis Ware, MD, Sangita Kapur, MD, & Christine Chhakchhuak, MD  |  December 17, 2015

Sternoclavicular joint involvement has rarely been reported in the context of active rheumatoid arthritis (RA).1 Traditionally, rheumatologists use serial radiographs of hands and feet to diagnose, monitor for progression or evaluate the response to treatment. The sternoclavicular (SC) joint is not a typical joint assessed for RA. However, the fact that it is a diarthrodial…

Filed under:ConditionsRheumatoid Arthritis Tagged with:ClinicalDiagnosisoutcomepatient careRARheumatoid arthritisSCsternoclavicular jointTreatment

Air Pollution: Is There an Association with Rheumatic Disease?

Gavin R. Sun, MD, Sasha Bernatsky, MD, Gilaad G. Kaplan, MD, & Cheryl Barnabe, MD  |  December 17, 2015

Interactions between an individual’s genetic background and their exposure to environmental factors are thought to result in a cascade of immune reactions, ultimately leading to the development of autoimmune diseases such as rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), systemic lupus erythematosus (SLE) and juvenile dermatomyositis.1,2 For example, an environmental factor that conclusively affects susceptibility…

Filed under:ConditionsRheumatoid ArthritisSystemic Lupus Erythematosus Tagged with:air pollutionenvironmentLupusRheumatic DiseaseRheumatoid arthritis

  • « Previous Page
  • 1
  • …
  • 225
  • 226
  • 227
  • 228
  • 229
  • …
  • 326
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences